Strate Labs closure: Peptide vendor shutdown wave 2026

Strate Labs, one of the longer-established vendors in the international trade with so-called research peptides - peptides officially sold only for laboratory and research purposes and labeled "Research Use Only" - has announced it will close on July 1, 2026. The storefront has carried a sitewide closure notice with clearance discounts since early June. The exit does not stand alone: it is part of a wave of vendor shutdowns that has hit the entire peptide gray market - that is, sales through international online shops operating under a "Research Use Only" disclaimer, sitting in a legal gray zone between legitimate research-chemical trade and unapproved medicines. Knock-on effects are reaching buyers in Germany and the EU.

What is unfolding here is not a single scandal - there is a bigger pattern behind it: more and more well-known vendors are giving up within just a few months because four lines of pressure are squeezing them at the same time - requirements from the FDA (U.S. drug regulator) and the EMA (European Medicines Agency), proceedings at the U.S. International Trade Commission (ITC, which handles import disputes between pharmaceutical companies and gray-market vendors), crackdowns by payment processors, and tighter customs enforcement. Anyone buying peptides needs to understand why the supply side is shrinking.

The essentials

• Strate Labs has posted a closure notice on its own storefront with discount pricing and will wind down operations on July 1, 2026.
• The vendor was already placed in default (meaning it lost the case automatically by failing to defend itself) in an ITC complaint filed by Eli Lilly in May 2024 and has been subject to a formal Cease and Desist Order from the U.S. International Trade Commission since April 15, 2025.
• The closure is the latest in a broader wave: Peptide Sciences shut on March 6, 2026, Science.bio closed in January 2026, and others have followed.
• Four forces are driving the exit: FDA warning letters and restrictions on compounding (custom-made pharmacy drugs), ITC cases from the big pharmaceutical companies, payment processor crackdowns (Stripe, PayPal), and tightened customs enforcement.
• For buyers in the EU this means: the "reliable gray market" many got used to over the last decade is measurably shrinking - residual stock, fraudsters and dubious successor sites are filling the gap.

Who is Strate Labs - and why is the vendor closing now?

Strate Labs is a Canadian research-chemical vendor with more than a decade of market presence and a catalog of over 55 peptide SKUs (product variants). These include popular research peptides for tissue repair (BPC-157, GHK-Cu), a hormone preparation (HCG), and highly sought-after weight-loss compounds from the incretin-based space - that is, GLP-1 receptor agonists such as semaglutide (the active ingredient in well-known weight-loss injections such as Ozempic, which Strate Labs sells under its in-house gray-market brand name "Semathin"), along with triple agonists such as retatrutide, which activate GIP and glucagon receptors in addition to GLP-1.

According to peptidesupply.org (June 2026), the storefront currently shows a "Closing July 1, 2026" banner alongside discount pricing across the catalog^[2].

No official reason for the closure has been published. What is on the public record: Strate Labs was named as a respondent in a complaint filed by Eli Lilly in March 2024 at the U.S. International Trade Commission (the ITC mentioned above) over tirzepatide imports (the active ingredient in Eli Lilly's Mounjaro, which is FDA-approved for Type 2 diabetes; the same compound is also sold as Zepbound for weight management) with alleged false designation of origin. In May 2024 the vendor was placed in default in that proceeding - meaning it received a default judgment after failing to defend itself and lost the case automatically. On April 15, 2025 the ITC issued a General Exclusion Order (a blanket import ban that automatically covers all tirzepatide imports) along with Limited Exclusion Orders and Cease and Desist Orders against Strate Labs, Arctic Peptides, Triggered Brand, SHS and AustroPeptide^[1]. Those orders mean: imports of the affected products into the United States have effectively been blocked since then - a major blow to a vendor that generated most of its revenue in the U.S. market.

Who else is closing? The 2025/2026 vendor shutdown wave at a glance

Exact scale varies. According to thepeptidecatalog.com, Peptide Sciences reportedly ran roughly USD 7.4 million in monthly online sales at the time of its shutdown. Public estimates for Science.bio and Strate Labs are lower, but both were among the most recognizable names in the "research use only" scene^[3]. The pattern is striking: nearly every closure came without warning, with a brief "voluntary" note and no guidance for open orders.

Which forces are driving the exits?

The vendor closures do not have a single trigger - four mutually reinforcing lines of pressure are squeezing them at the same time, as peptidesupply.org and thepeptidecatalog.com report^[2][3].

1. Regulatory pressure

The U.S. drug regulator FDA sent an unprecedented wave of warning letters to peptide vendors in 2025 and 2026. On April 7, 2026 seven online sellers were hit at once; in mid-June 2026 another 25 telehealth companies (online clinic services that issue prescriptions via video consultation) faced letters over misleading compounding claims (claims about selling custom-made pharmacy drugs). Vendors that sold peptides under the "Research Use Only" disclaimer explained above (or "Not for Human Consumption", meaning "not for human use") - but also offered bacteriostatic water (which is specifically used to mix peptides for injection) and dosing instructions - saw the disclaimer dismissed as a sham. The EU is moving in parallel: the EMA (European Medicines Agency), the HMA (the network of national EU drug regulators), and the UK's MHRA (Medicines and Healthcare products Regulatory Agency) are pulling in the same direction. The EMA/HMA warnings on illegal GLP-1 drugs (weight-loss injection active ingredients such as Ozempic) plus the MHRA raid that seized 12,000 doses in the UK on May 28, 2026 show that regulators on both sides of the Atlantic are pulling together^[4].

2. Pharmaceutical ITC cases

Eli Lilly filed a complaint in 2024 at the U.S. International Trade Commission (the same ITC mentioned above) against a list of tirzepatide vendors (the active ingredient in Mounjaro) that included Strate Labs, Arctic Peptides, Triggered Brand, SHS and AustroPeptide. The outcome in April 2025 was the General Exclusion Orders (comprehensive import bans) described above, effectively banning tirzepatide product imports into the U.S., plus Cease and Desist Orders against the named vendors^[1]. Novo Nordisk ran a comparable wave against semaglutide sellers in 2025. For smaller "research" shops this means: even if you operate in a regulatory gray zone, an ITC order can cut you off from the U.S. market overnight - no FDA warning letter required, no administrative proceeding.

3. Payment processors pulling out

Stripe, PayPal and the major acquiring banks (banks that provide merchant accounts for credit-card processing) had long been uneasy about peptide merchants. Every headline about contamination, liver damage or severe allergic reactions raised their risk exposure. Several vendors lost their merchant accounts not because of an FDA action directly, but because their card acquirer terminated the relationship. A peptide company can survive regulatory uncertainty for a while; without card payments it is effectively dead in e-commerce. This combination - gray-market reputation plus banking risk - explains a large share of the sudden, silent closures.

4. Customs and supply chains

U.S. authorities such as the FDA and the U.S. border agency CBP (Customs and Border Protection) have tightened border controls. Shipments that previously cleared routinely are now held, tested or seized. Lead times that used to run two weeks stretched to six or eight weeks - or became indefinite. That hits vendors with thin margins and limited inventory buffers hardest. The picture is amplified by reports of catastrophically contaminated products - the FDA warning letters of April 2026 to seven peptide shops are the most visible example, but far from the only one.

What does this mean for buyers in Germany and the EU?

Anyone in Germany ordering peptides from international "research" vendors is directly affected by this wave - even though no German authority is involved. peptidehub.bio (June 2026) stresses that regulators on both sides of the Atlantic are now pulling together: the MHRA raid in the UK, EMA/HMA warnings on illegal GLP-1 drugs (weight-loss injection active ingredients such as Ozempic), German authorities running priority actions^[4]. Three points to keep in mind right now:

1. Residual stock and fake shops: when an established vendor closes, successor domains imitating the brand appear within weeks. Orders through such domains are a classic fraud risk - the Vendor Radar tracks this on an ongoing basis.
2. Batch and traceability: vendors shutting down in the course of the wave typically take their COAs (Certificates of Analysis - lab confirmations of content and purity) offline. Anyone still using stock from these shops no longer has any independent confirmation of content, purity, or sterility - the latest gray-market report shows that independent verification options for such products barely exist anymore.
3. Delivery times and customs risk: anyone now switching to non-European vendors should expect significantly longer delivery times and a higher risk of shipments being held by German customs.

Strate Labs, with its July 1, 2026 closure date, is only the most recent example in a chain. More closures are likely in the coming weeks - voluntary or through enforcement. Before placing an order with a vendor you have not used before, check the Vendor Radar and the warning list: I collect reports there on shops currently flagged as problematic.

No medical advice. Peptipedia provides independent, non-commercial information. For health questions consult a physician or pharmacist.